glucagon has been researched along with xenin 25 in 10 studies
| Studies (glucagon) | Trials (glucagon) | Recent Studies (post-2010) (glucagon) | Studies (xenin 25) | Trials (xenin 25) | Recent Studies (post-2010) (xenin 25) |
|---|---|---|---|---|---|
| 26,039 | 1,498 | 3,054 | 72 | 6 | 38 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eberle, C; Feurle, GE; Fried, M; Hamscher, G; Heger, M; Niebergall-Roth, E; Singer, MV; Teyssen, S | 1 |
| Egido, EM; Hernández, R; Marco, J; Rodríguez-Gallardo, J; Silvestre, RA | 1 |
| Schick, RR; Schusdziarra, V; Zimmermann, JP | 1 |
| Crimmins, DL; Dunai, J; Ladenson, JH; Patterson, BW; Polonsky, KS; Reeds, DN; Tran, HD; Villareal, DT; Wallendorf, MJ; Wice, BM | 1 |
| Chowdhury, S; Crimmins, DL; Dunai, J; Griest, TA; Laciny, E; Ladenson, JH; Patterson, BW; Polonsky, KS; Reeds, DN; Rometo, DA; Tran, HD; Wallendorf, MJ; Wang, S; Wice, BM | 1 |
| Oestricker, L; Patterson, BW; Reeds, DN; Sterl, K; Wallendorf, MJ; Wang, S; Wice, BM | 1 |
| Chowdhury, S; Dunai, J; Kilpatrick, R; Oestricker, LZ; Patterson, BW; Reeds, DN; Wallendorf, MJ; Wang, S; Wice, BM | 1 |
| Dunai, J; Kilpatrick, CR; Oestricker, LZ; Patterson, BW; Reeds, DN; Sterl, K; Wallendorf, MJ; Wang, S; Wice, BM | 1 |
| Craig, SL; Gault, VA; Hamscher, G; Irwin, N; McClean, S | 1 |
| Hayashi, H; Onaga, T; Yasui, Y | 1 |
4 trial(s) available for glucagon and xenin 25
| Article | Year |
|---|---|
Xenin-25 amplifies GIP-mediated insulin secretion in humans with normal and impaired glucose tolerance but not type 2 diabetes.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucose; Glucose Intolerance; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Insulin; Insulin Secretion; Male; Middle Aged; Neurotensin | 2012 |
Xenin-25 delays gastric emptying and reduces postprandial glucose levels in humans with and without type 2 diabetes.
Topics: Adult; Biomarkers; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Infusions, Intravenous; Insulin; Male; Middle Aged; Missouri; Neurotensin; Postprandial Period; Receptors, Neurotensin; Time Factors; Treatment Outcome | 2014 |
Metabolic responses to xenin-25 are altered in humans with Roux-en-Y gastric bypass surgery.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diarrhea; Female; Gastric Bypass; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Insulin; Insulin Secretion; Male; Middle Aged; Neuropeptide Y; Neurotensin; Pancreatic Polypeptide | 2016 |
Hormonal Responses to Cholinergic Input Are Different in Humans with and without Type 2 Diabetes Mellitus.
Topics: Administration, Oral; Adult; Bethanechol; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Hormones; Humans; Insulin; Islets of Langerhans; Male; Middle Aged; Muscarinic Agonists; Neurotensin; Non-Randomized Controlled Trials as Topic; Pancreatic Polypeptide; Postprandial Period | 2016 |
6 other study(ies) available for glucagon and xenin 25
| Article | Year |
|---|---|
Gastroenteropancreatic effects of xenin in the dog.
Topics: Animals; Dogs; Female; Gastric Acid; Gastric Mucosa; Gastrointestinal Hormones; Gastrointestinal Motility; Glucagon; Infusions, Intravenous; Islets of Langerhans; Jejunum; Male; Muscle, Smooth; Neurotensin; Pancreas; Pancreatic Juice; Pancreatic Polypeptide; Pentagastrin; Peptides; Vasoactive Intestinal Peptide | 1997 |
Stimulatory effect of xenin-8 on insulin and glucagon secretion in the perfused rat pancreas.
Topics: Animals; Arginine; Carbachol; Dose-Response Relationship, Drug; Drug Synergism; Gastric Mucosa; Glucagon; Insulin; Insulin Secretion; Male; Neurotensin; Pancreas; Peptide Fragments; Peptides; Perfusion; Rats; Rats, Wistar; Somatostatin; Time Factors | 2003 |
Importance of orexigenic counter-regulation for multiple targeted feeding inhibition.
Topics: Animals; Appetite Depressants; Eating; Glucagon; Glucagon-Like Peptide 1; Homeostasis; Male; Naloxone; Narcotic Antagonists; Neuropeptide Y; Neuropeptides; Neurotensin; Peptide Fragments; Peptides; Protein Precursors; Rats; Rats, Wistar; Receptors, Neuropeptide Y | 2004 |
Cholinergic signaling mediates the effects of xenin-25 on secretion of pancreatic polypeptide but not insulin or glucagon in humans with impaired glucose tolerance.
Topics: Adult; Atropine; Blood Glucose; Cross-Over Studies; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucose Intolerance; Heart Rate; Humans; Insulin; Insulin Secretion; Male; Middle Aged; Neurotensin; Pancreatic Polypeptide; Receptors, Cholinergic; Signal Transduction | 2018 |
Effects of an enzymatically stable C-terminal hexapseudopeptide fragment peptide of xenin-25, ψ-xenin-6, on pancreatic islet function and metabolism.
Topics: Animals; Cell Line; Glucagon; Glucose; Humans; Hypoglycemic Agents; Insulin Secretion; Insulin-Secreting Cells; Mice; Neurotensin | 2019 |
Effects of xenin-25 on insulin and glucagon secretions in healthy conscious sheep.
Topics: Animals; Blood Glucose; Glucagon; Insulin; Insulin Secretion; Neurotensin; Sheep | 2021 |